ClinicalTrials.gg
CompletedNCT01668641Updated Jun 27, 2013

Dose-ranging Study With GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients

A Phase 2 interventional study of GLPG0634 and Placebo in Rheumatoid Arthritis, sponsored by Galapagos NV. Completed at 19 sites in 4 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2013-06-27.

Sponsored by Galapagos NV · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
91
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing GLPG0634 in Arthritis, Rheumatoid — 4 open to participants now, 4 under way, none of them phase 3. GLPG0634 · Arthritis, Rheumatoid.

Enrollment
12th of 17
91 · median 287
Started
2012
the only one that year
Phase 2
6 of 17
none open now
Registered
2nd of 17
by date
Lead sponsor
6 of 17
Galapagos NV

Among the 17 studies testing GLPG0634 in Arthritis, Rheumatoid, this one is the 12th largest by enrollment, is the only one that started in 2012, is one of 6 in phase 2, and was the 2nd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 17 studies testing GLPG0634 in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About GLPG0634

GLPG0634: first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing GLPG0634 in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

  • Ninety patients suffering from active rheumatoid arthritis despite continued treatment with methotrexate will be evaluated for improvement of disease activity when taking GLPG0634 (4 different doses will be evaluated) or matching placebo for 4 weeks.
  • During the course of the study, patients will also be examined for any side effects that may occur, and the amount of GLPG0634 present in the blood as well as the effects of GLPG0634 on disease- and mechanism of action-related parameters in the blood will be determined.
03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Methotrexate insufficient responders
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have active RA as shown by five or more swollen joints (from the 66-joint count), five or more tender joints (from 68-joint count), and a serum CRP ≥1.0 mg/dL;
  • Have received methotrexate for 12 weeks or longer and at a stable dose of 7.5 to 25 mg/week for at least 4 weeks prior to screening and willing to continue on this regimen for the duration of the study;
  • If taking oral , these should be at a dose ≤10 mg/day of prednisone or prednisone equivalent and stable for at least 4 weeks prior to screening;
  • If taking non-steroidal anti-inflammatory drugs (NSAIDs), these must be at a stable dose for at least 2 weeks prior to screening;
  • Female subjects must have a negative pregnancy test unless they are surgically sterile or have been for at least one year;
  • Women of must use a medically acceptable means of and agree to continue its use during the study and for at least 12 weeks after the last dose of study drug.
  • Sexually active men must agree to use a medically acceptable form of contraception during the study and continue its use for at least 3 months after the last dose of study drug; and
  • Able and willing to sign the prior to screening evaluations and agree to schedule of assessments.

Exclusion criteria

Exclusion Criteria:

  • Treatment with disease-modifying antirheumatic drugs (DMARDs), other than background methotrexate;
  • Current or previous RA treatment with a biological agent, with the exception of biologics administered in a clinical study setting more than six months prior to screening (12 months for rituximab or other B cell depleting agents);
  • Previous treatment at any time with a cytotoxic agent, other than methotrexate, before screening;
  • Previous use of the study drug GLPG0634;
  • Receipt of an intra-articular or parenteral injection within 4 weeks prior to screening;
  • Known to study drug ingredients or a significant allergic reaction to any drug as determined by the Investigator;
  • Positive serology for HIV1 or 2 or or C, or any history of hepatitis from any cause with the exception of hepatitis A;
  • History of any inflammatory rheumatological disorders other than RA;
  • History of tuberculosis (TB) infection
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
91 participants (actual)

Study arms

  • Experimental
    capsule, 30mg GLPG0634 once a day

    3 capsules of 10 mg once a day

    Drug: GLPG0634

  • Experimental
    capsules, 75mg GLPG0634 once a day

    3 capsules of 25mg once a day

    Drug: GLPG0634

  • Experimental
    capsules, 150mg GLPG0634 once a day

    3 capsules of 50mg once a day

    Drug: GLPG0634

  • Experimental
    capsules, 300mg GLPG0634 once a day

    3 capsules of 100mg once a day

    Drug: GLPG0634

  • Placebo comparator
    capsules, placebo once a day

    3 capsules placebo once a day

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. The number of patients with an ACR20 score at Week 4 as a measure of efficacy

    To preliminary evaluate the efficacy of GLPG0634 compared to placebo in terms of the proportion of subjects achieving an ACR20 response at Week 4

    Time frame: Week 4 (end of treatment visit)

Secondary outcomes

  1. The number of patients with ACR20/50/70 response, time to response and DAS28 score at every visit as a measure of efficacy

    To evaluate the efficacy of GLPG0634 compared to placebo in terms of ACR response criteria at every visit (ACR20, ACR50, ACR70), time to response, and disease status (DAS28\[C-reactive protein, CRP\]

    Time frame: From Day -1 up to end of treatment visit (week 4)

  2. The number of patients with adverse events, abnormal lab tests, vital signs and ECG as a measure of safety and tolerability

    To evaluate the safety and tolerability of GLPG0634 in comparison with placebo in terms of adverse events (AEs), laboratory test abnormalities, vital signs and electrocardiogram (ECG)

    Time frame: From screening up to 10 days after last dose

  3. The plasma levels of GLPG0634 as a measure of PK

    To characterize the pharmacokinetics (PK) of GLPG0634 by measuring the amount of GLPG0634 in the plasma

    Time frame: Week 1, week 2 and week 4 visits

  4. The plasma levels of GLPG0634 and MTX as a measure of PK

    To explore the potential interaction of GLPG0634 on MTX by assessing steady state PK in an 8-hour sampling at Day -1 and at Week 2 or Week 4 visit in a subset of patients

    Time frame: Day -1 and Week 2 or 4 visit (8 hour-sampling)

  5. The levels of immune- and inflammation-related parameters in plasma as a measure of PD

    To characterize the pharmacodynamics (PD) of GLPG0634 by measuring the levels of immune- and inflammation-related parameters in plasma

    Time frame: Day -1, Week 1, week 2 and week 4 visits

07

Study locations

19 sites
  • Budai Irgalamsrendi Korhaz, II. Reumatologia Osztaly
    Budapest, Hungary
  • Orszagos Reumatologiai es Fizioterapias Intezet, I. Reumatologia Osztaly
    Budapest, Hungary
  • Markhot Ferenc Korhaz, Reumatologiai Osztaly
    Eger, Hungary
  • Pest Megyei Flor Ferenc Korhaz, Reumatologiai es Fizioterapias Osztaly
    Kistarcsa, Hungary
  • IMSP Institutel de Cardiologie
    Chisinau, Moldova, Republic of
  • State Healthcare Institution of city Moscow 'City Clinical Hospital #7'
    Moscow, Russian Federation
  • State Healthcare Institution 'Ryazan Regional Cardiology Dispensary'
    Ryazan, Russian Federation
  • Saint-Petersburg State Healthcare Institution 'City Hospital #26'
    Saint-Petersburg, Russian Federation
  • Saint-Petersburg State Healthcare Institution 'City Mariinskiy Hospital'
    Saint-Petersburg, Russian Federation
  • Municipal Clinical Healthcare Institution 'Medical-Sanitary Unit of Novoyaroslavskiy Oil Refinery'
    Yaroslavl, Russian Federation
  • Chernivtsi Regional Clinical Hospital
    Chernivtsi, Ukraine
  • State Institution 'Institute of Urgent and Recovery Surgery n.a. V.K. Gusaka' of AMS of Ukraine
    Donetsk, Ukraine
  • Communal Institution of Healthcare
    Kharkiv, Ukraine
  • Institution of Therapy of AMS of Ukraine
    Kharkiv, Ukraine
  • State Institution 'Institute of Microbiology and Immunology of AMS of Ukraine'
    Kharkiv, Ukraine
  • State Institution 'Republican Clinical Hospital of MoH of Ukraine'
    Kiev, Ukraine
  • Lutsk City Clinical Hospital
    Lutsk, Ukraine
  • Vinnytsa Regional Clinical Hospital
    Vinnytsa, Ukraine
  • Zaporizhzhia Regional Clinical Hospital
    Zaporizhzhia, Ukraine
08

References and documents

Publications

  • Vanhoutte F, Mazur M, Voloshyn O, Stanislavchuk M, Van der Aa A, Namour F, Galien R, Meuleners L, van 't Klooster G. Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials. Arthritis Rheumatol. 2017 Oct;69(10):1949-1959. doi: 10.1002/art.40186. Epub 2017 Aug 31. PubMed 28622463 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of Sep 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2012
First posted
Aug 20, 2012
Start
May 2012
Primary completionActual
Sep 2012
CompletionActual
Oct 2012
Last update
Jun 27, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01668641
Lead sponsor
Galapagos NV
Responsible party
Sponsor
First posted
Aug 20, 2012
Start date
May 2012
Primary completion
Sep 2012
Completion
Oct 2012
Last update
Jun 27, 2013

Study contacts

Frédéric Vanhoutte, MD
study director · Galapagos NV

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GLPG0634

Start the discussion